Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot improve sensitivity?
The O-Shot may help support genital sensitivity in selected patients, especially where reduced sensation is linked with local tissue quality, dryness, discomfort, low-oestrogen change, or arousal response. reduced sensitivity can come from medication, nerve health, pelvic floor tension, pain, menopause, diabetes, surgery, childbirth, or stimulation factors.
Direct answer
The O-Shot may help support genital sensitivity in selected patients, especially where reduced sensation is linked with local tissue quality, dryness, discomfort, low-oestrogen change, or arousal response. reduced sensitivity can come from medication, nerve health, pelvic floor tension, pain, menopause, diabetes, surgery, childbirth, or stimulation factors.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
VEGF
Increases angiogenesis and microvascular permeability.
PDGF
Stimulates cell proliferation, collagen synthesis, and wound healing.
TGF-β
Regulates production of collagen types I and III and mesenchymal cell proliferation.
IGF (1 and 2)
Enhances protein synthesis and regulates cell differentiation.
Important safety note
Common: Transient edema, minor ecchymosis, and minor post-procedural spotting.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
Research Limitations: Current data are restricted by small sample sizes and the subjective nature of self-reported questionnaires (FSFI/FSDS-R), leaving room for potential placebo effects. Device Distinctions: Unlike transvaginal laser therapy, which utilizes controlled thermal injury, PRP is an autologous, non-antigenic biological.
Clinical context
Research Limitations: Current data are restricted by small sample sizes and the subjective nature of self-reported questionnaires (FSFI/FSDS-R), leaving room for potential placebo effects.
Evidence
Symptoms
Alternatives
What it means
Research Limitations: Current data are restricted by small sample sizes and the subjective nature of self-reported questionnaires (FSFI/FSDS-R), leaving room for potential placebo effects.
Why it happens
Device Distinctions: Unlike transvaginal laser therapy, which utilizes controlled thermal injury, PRP is an autologous, non-antigenic biological.
Evidence limits
Clinical Adoption Context: FSD remains significantly underdiagnosed; only 14% of women discuss sexual concerns with physicians.
Treatment fit
Suitability depends on history, symptoms, examination where appropriate and discussion of alternatives.
What this means in practice
Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate. Centrifugation: A two-spin method is utilized to maximize concentration: First Spin: 2500 rpm for 3 minutes. Second Spin: 4000 rpm for 15 minutes. Activation: 0.
Treatment Frequency: Protocols range from a single "O-Shot" session to a structured sequence of four sessions spaced 4–6 weeks apart.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Research Limitations: Current data are restricted by small sample sizes and the subjective nature of self-reported questionnaires (FSFI/FSDS-R), leaving room for potential placebo effects.
It protects safety
Common: Transient edema, minor ecchymosis, and minor post-procedural spotting.
It reviews alternatives
Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate.
It sets expectations
Treatment Frequency: Protocols range from a single "O-Shot" session to a structured sequence of four sessions spaced 4–6 weeks apart.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate. Centrifugation: A two-spin method is utilized to maximize concentration: First Spin: 2500 rpm for 3 minutes. Second Spin: 4000 rpm for 15 minutes. Activation: 0.
Consultation priorities
Analgesia: Application of a compounded BLT cream (Bupivacaine 20%, Lidocaine 8%, Tetracaine 8%) to the clitoris and anterior vaginal wall for 20–60 minutes.
Consent
Aftercare
Follow-up
Before treatment
Analgesia: Application of a compounded BLT cream (Bupivacaine 20%, Lidocaine 8%, Tetracaine 8%) to the clitoris and anterior vaginal wall for 20–60 minutes.
During care
Procedure: While the patient achieves analgesia, the PRP is processed.
Aftercare
Immediate Post-Procedure: Transient edema is expected. Patients may manage minor soreness with acetaminophen (avoiding NSAIDs for 2–6 weeks).
When to reassess
Restrictions: Patients must avoid sexual intercourse, tampons, heavy exercise, and swimming pools for 2 to 7 days.
Practical expectations
Treatment Frequency: Protocols range from a single "O-Shot" session to a structured sequence of four sessions spaced 4–6 weeks apart.
Centrifugation: A two-spin method is utilized to maximize concentration:
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: Sensitivity is one single symptom.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: More sensation always means better sex.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: PRP can resolve every cause of reduced sensation.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Device Distinctions: Unlike transvaginal laser therapy, which utilizes controlled thermal injury, PRP is an autologous, non-antigenic biological.
Alternatives
Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Common: Transient edema, minor ecchymosis, and minor post-procedural spotting.
Are alternatives clear?
Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Common: Transient edema, minor ecchymosis, and minor post-procedural spotting.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Common: Transient edema, minor ecchymosis, and minor post-procedural spotting.
Bleeding or discharge
Specific/Rare: Extreme or continuous arousal, including ejaculatory orgasm and sexual arousal with urination (typically resolving within 1–2 weeks).
Infection signs
Antiplatelet/anticoagulant therapy or recent NSAID use (which dampens the requisite inflammatory cascade).
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The best page should convert a broad commercial keyword into a precise symptom-mapping tool.
Clinical reality
- Research Limitations: Current data are restricted by small sample sizes and the subjective nature of self-reported questionnaires (FSFI/FSDS-R), leaving room for potential placebo effects.
- Device Distinctions: Unlike transvaginal laser therapy, which utilizes controlled thermal injury, PRP is an autologous, non-antigenic biological.
- Clinical Adoption Context: FSD remains significantly underdiagnosed; only 14% of women discuss sexual concerns with physicians.
Timeline and expectations
- Treatment Frequency: Protocols range from a single "O-Shot" session to a structured sequence of four sessions spaced 4–6 weeks apart.
- Biological Timeline: Cellular transformation follows a specific cycle: the fibrin matrix typically resolves within a 2-week window, followed by an 8-week period of replacement with new tissue growth.
- Domain-Specific Trajectories:
- Arousal, Lubrication, and Orgasm: Show the highest statistical significance in improvement (p<0.05).
- Satisfaction and Pain: While clinical trends suggest improvement, these domains often fail to reach statistical power in pilot groups (e.g., Runels reported p=0.28 for satisfaction and p=0.25 for pain).
Practical logistics
- Preparation: Peripheral blood (10–60 mL) is drawn into sodium citrate.
- Centrifugation: A two-spin method is utilized to maximize concentration:
- First Spin: 2500 rpm for 3 minutes.
- Second Spin: 4000 rpm for 15 minutes.
- Activation: 0. 5 mL of Calcium Chloride (10%) is added to the PRP isolate to trigger the thrombin cascade.
- Injection Technique:
Research sources
- Runels C, et al. (2014). "A Pilot Study of the Effect of Localized Injections of Autologous Platelet Rich Plasma (PRP) for the Treatment of Female Sexual Dysfunction." Journal of Women's Health Care.
- Salam KA, et al. (2022). "Value of injection of plasma-rich platelets in the vaginal and the clitoris in cases with female sexual dysfunction." Ginekologia i Poloznictwo.
- Sukgen G, et al. (2023). "Platelet rich plasma (PRP) for vaginal tightening: A new approach." Pelviperineology.
- NICE (2021). "IP overview: transvaginal laser therapy for stress urinary incontinence."
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Full Research Bibliography (10 Sources)
Educational only. Autologous Platelet Rich Plasma (PRP) for Female Sexual Dysfunction (FSD) is currently considered an investigational treatment. Clinical results are variable and contingent upon individual medical history and the specific etiology of the dysfunction. This document provides clinical information only and is not a substitute for professional medical consultation, diagnosis, or treatment. Results vary. Not a cure.
